<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16697">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991509</url>
  </required_header>
  <id_info>
    <org_study_id>LBR-101-011</org_study_id>
    <nct_id>NCT01991509</nct_id>
  </id_info>
  <brief_title>Safety and Bioavailability of IV and SC LBR-101</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labrys Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labrys Biologics Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and blood levels of LBR-101
      when administered intravenously or subcutaneously to healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Relative bioavailability of IV versus SC Administration of LBR-101</measure>
    <time_frame>30 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Bioavailability and Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>LBR-101 IV Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LBR-101 Dose 1 Administered Intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBR-101 SC Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LBR-101 Dose 1 Administered Subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Administered Intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Administered Subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBR-101 Dose 2 IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LBR-101 Dose 2 Administered Intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBR-101 Dose 2 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LBR-101 Dose 2 Administered Subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LBR-101 IV</intervention_name>
    <description>LBR-101 Administered Intravenously</description>
    <arm_group_label>LBR-101 IV Dose 1</arm_group_label>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_label>LBR-101 Dose 2 IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LBR-101 SC</intervention_name>
    <description>LBR-101 Administered Subcutaneously</description>
    <arm_group_label>LBR-101 SC Dose 1</arm_group_label>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_label>LBR-101 Dose 2 SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally Healthy, Signed Approved Informed Consent, BMI 17.5-34.5 kg/m2, Willing and
             able to comply with CRU rules regulations and study schedule

        Exclusion Criteria:

          -  Clinically significant medical or psychiatric condition, Febrile illness within 5
             days of dosing, Pregnant or Nursing Females. History of alcoholism, drug addiction or
             positive drug/alcohol screen, History of hypersensitivity to injected proteins or
             monoclonal antibodies, Unwilling or unable to comply with the protocol specified
             lifestyle guidelines, Investigational site staff members, Use of 3 or more
             prescription or non-prescription medications daily, Acetaminophen use in doses of
             higher than 1 g or more/day, Daily Aspirin use in higher than 325 mg/day,  Treatment
             with an investigational drug within 30 days of dosing, Use of biologics within 6
             months of screening, Any clinically significant abnormality in the 12-Lead ECG,
             Positive result for HIV, Hepatitis B, or Hepatitis C, Any clinically significant
             abnormalities in Blood Chemistry Hematology or Urinalysis, Positive Pregnancy Test.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo Bigal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor Chief Medical Officer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Escandon, PhD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor Clinical VP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
